Sign in
Taking people in United StatesPhase 1

Cagrilintide for people with obesity who could not tolerate GLP-1 medicines

Tests cagrilintide against placebo in adults with obesity who stopped GLP-1 medicines.

Key facts

Who runs it
Novo Nordisk A/S
Where
Amarillo, Austin, Bristol, Conyers, Fleming Island, Jacksonville, Monroe, North Charleston, Pembroke Pines, Statesville, Walnut Creek, Weston, and Wilmington, United StatesSee the 13 sites
Trial code
Registry title
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Status
Recruiting
Phase
Phase 1
People taking part
114 people, planned
Started
29 May 2026
Expected to end
19 Nov 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cagrilintide
  • Placebo (matched to Cagrilintide)
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity who stopped GLP-1-RA medicines because of stomach and gut side effects. It compares Cagrilintide with placebo.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Body mass index (BMI) of 30.0 kg/m^2 or more.
Earlier treatment
Must have taken GLP-1-RA medicines and stopped mainly because of gastrointestinal side effects. Restarting GLP-1-RA treatment must not be possible, based on medical history and the investigator's judgement. No GLP-1-RA treatment in the 8 weeks before screening.
Biomarker or test result
HbA1c below 6.5 percent (48 mmol/mol) at screening.

Main reasons for not taking part

  • Pregnant, breast-feeding, planning pregnancy, or able to have children and not using highly effective contraception
  • History of type 1 or type 2 diabetes
  • Medicine for diabetes or pre-diabetes in the 90 days before screening
  • Medicine for weight management in the 8 weeks before screening
  • GLP-1-RA medicine for any reason in the 8 weeks before screening

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Male or female (sex at birth)
  • Age 18 years or above at the time of signing the informed consent
  • History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation
  • Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement
  • Body mass index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg/m\^2)

Who cannot take part

  • Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening
  • Treatment with any medication prescribed for the indication of weight management within 8 weeks before screening
  • History of type 1 or type 2 diabetes
  • Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening
  • Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening
  • Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods

This trial is currently available in United States.

  • Amarillo Medical SpecialistsAmarillo, United StatesContact: Novo NordiskTaking people
  • Elligo Clin Res CentreAustin, United StatesContact: Novo NordiskTaking people
  • Holston Medical Group_BristolBristol, United StatesContact: Novo NordiskTaking people
  • Hope Clin Res & WellnessConyers, United StatesContact: Novo NordiskNot yet recruiting
  • Northeast Research InstituteFleming Island, United StatesContact: Novo NordiskTaking people
  • Jacksonville Ctr for Clin ResJacksonville, United StatesContact: Novo NordiskTaking people
  • Monroe Biomedical Research, LLCMonroe, United StatesContact: Novo NordiskTaking people
  • Coastal Carolina Research CtrNorth Charleston, United StatesContact: Novo NordiskNot yet recruiting
  • Center for Diab,Obes & MetabPembroke Pines, United StatesContact: Novo NordiskTaking people
  • PHC AccelacareStatesville, United StatesContact: Novo NordiskNot yet recruiting
  • Diablo Clinical Research, Inc.Walnut Creek, United StatesContact: Novo NordiskTaking people
  • Encore Medical Research of WestonWeston, United StatesContact: Novo NordiskTaking people
  • AccellacareWilmington, United StatesContact: Novo NordiskTaking people

About the trial

What the trial wants to find out

The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.

The 2 groups in the trial

  • CagrilintideTreatment being tested

    Participants will receive Cagrilintide for 26 weeks.

  • PlaceboPlacebo, for comparison

    Participants will receive placebo matched to Cagrilintide for 26 weeks.

    Treatment: Placebo (matched to Cagrilintide)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study
Plain-language title
Cagrilintide for people with obesity who could not tolerate GLP-1 medicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 October 2026